Dual ET<sub>A</sub>‐ET<sub>B</sub> receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction
Dual ERA macitentan improved both LV and RV diastolic dysfunction. This was associated with improved coronary vasodilation, diminished cardiac oxidative stress and improved blood composition. These results suggest that antagonizing the ET system with macitentan is a promising approach to treat HFpEF and its complications.
Authors
- Vincent Richard (ORCID: https://orcid.org/0000-0003-0590-0158)
- Marianne Lachaux
- Sylvanie Renet
- Matthieu Soulié (ORCID: https://orcid.org/0000-0002-5169-1628)
- Paul Mulder (ORCID: https://orcid.org/0000-0002-5936-5704)
- Lionel Nicol (ORCID: https://orcid.org/0000-0002-7820-4148)
- Najah Harouki (ORCID: https://orcid.org/0000-0002-2830-6832)
- Magali Vercauteren
- Francesca Lockwood (ORCID: https://orcid.org/0000-0002-8426-9589)
- Marc Iglarz
- Jérémy Bellien (ORCID: https://orcid.org/0000-0002-0383-2342)
- Anaïs Dumesnil
Institutions
- Inserm (FR)
- University of Oslo (NO)
- Idorsia (Switzerland) (CH)
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- Fundamental and Clinical Pharmacology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1111/fcp.70006
- Citations
- 3
- Primary Topic
- Nitric Oxide and Endothelin Effects
- Type
- article
- Field-Weighted Citation Impact
- 3.49
Funders
- European Commission
- Fédération Française de Cardiologie
- Région Normandie
- Horizon 2020 Framework Programme
- European Regional Development Fund